Company Overview of Pulmatrix, Inc.
Pulmatrix, Inc., a biopharmaceutical company, develops inhaled therapies that harness the body’s natural host defenses and immune response. It offers inhaled cationic airway lining modulators to prevent and treat various respiratory diseases, such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company’s inhaled cationic airway lining modulators are also used to prevent and treat various respiratory infections, such as influenza, influenza-like illness, rhinovirus, ventilator-associated pneumonia, respiratory syncytial virus, parainfluenza, adenovirus, allergic rhinitis, and rhinovirus in compromised and healthy individuals. The company was incorporated in 2003 and...
99 Hayden Avenue
Lexington, MA 02421
Founded in 2003
Key Executives for Pulmatrix, Inc.
Chief Executive Officer and Director
Co-Founder and Chairman of the Scientific Advisory Board
Co-Founder, Director and Member of the Scientific Advisory Board
Co-Founder and Member of the Scientific Advisory Board
Vice President of Finance and Operations
Compensation as of Fiscal Year 2014.
Pulmatrix, Inc. Key Developments
Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015
Dec 19 14
Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.
Pulmatrix, Inc. Announces Positive Results from Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients
Oct 28 13
Pulmatrix, Inc. announced the completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product from the company's novel iSPERSE™ inhaled dry powder technology. The first part of the Phase 1B clinical trial evaluated the safety, tolerability and the pharmacokinetic/pharmacodynamic profile of single ascending doses of PUR0200 in patients with moderate COPD. The first part of the Phase 1B study evaluated pharmacokinetics and pulmonary function after administration of four single ascending doses of PUR0200 in 24 patients with moderate COPD. All doses of PUR0200 were generally well tolerated and were associated with increases in lung function, as measured by peak and trough forced expiratory volume (FEV1) from baseline, and compared to placebo dosing. Pharmacokinetic assessments affirmed the effective lung delivery of PUR0200 and the iSPERSE platform and compared favorably to published data on lactose blend formulations. The data from the first part of the study will be used to inform dose selection for the second part of the study, a cross-over design study that starts this month and includes an active comparator arm. The study is targeted for completion in the first quarter of 2014 and data from both parts of the study will be presented at a future scientific meeting.
Pulmatrix, Inc. Announces Initiation of Phase IB Clinical Study of PUR0200 in Chronic Obstructive Pulmonary Disease
Jul 22 13
Pulmatrix, Inc. announced the initiation of a phase IB clinical study in chronic obstructive pulmonary disease (COPD) with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product emerging from the company's iSPERSE(TM) technology, a novel inhaled dry powder delivery platform. The clinical trial will evaluate the safety, tolerability and the pharmacokinetic/pharmacodynamic profile as well as dose response of PUR0200 in moderate COPD patients. GOLD Stage 2/3 COPD patients will be enrolled in a five-way placebo controlled crossover study. PUR0200 was designed using the Pulmatrix proprietary iSPERSE particle engineering technology platform, an engineered particle technology that facilitates flow rate independent, high efficiency drug delivery to the lungs. The PUR0200 bronchodilator therapy is designed to provide for improved performance over currently marketed therapeutics. The study is being conducted by Quotient Clinical in Nottingham, England in conjunction with Professor Dave Singh at the Medicines Evaluation Unit in Manchester, England, and the Drug Product is being manufactured and supplied real-time by Quotient Clinical using its flexible Translational Pharmaceutics platform.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|